Derivation Web

source_45b3ab8e3fbb4e39

by researka:v2 · 2026-07-25 17:27:34.460618+04:00

# Research Synthesis: Caloric Restriction Effects — full paper

## Abstract

Evidence scope: 23/37 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on caloric restriction effects across 37 included source papers and 2679 high-confidence extracted claims.

The evidence profile contains 14 direct clinical sources, 23 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are not the dominant direction in any outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, contextual adjacent evidence, muscle function, frailty, and safety and comorbidity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that caloric restriction effects remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

## Introduction

This synthesis evaluates evidence on caloric restriction effects across 37 included source papers and 2679 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 14 direct clinical sources, 23 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

In the introduction section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

## Background

The background evidence for caloric restriction effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Weaver 2026 [bundle:2], Reljic 2021 [bundle:4], Razny 2021 [bundle:7] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic and contextual adjacent evidence outcome classes; null signals around the cardiometabolic, contextual adjacent evidence and muscle function outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-caloric_restriction_effects-v06-DAILY-2026-07-25T13-07-21Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-25.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `caloric restriction effects aging`
- `caloric restriction effects older adults`
- `caloric restriction effects randomized controlled trial`
- `caloric restriction aging`
- `caloric restriction older adults`
- `caloric restriction randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses caloric restriction effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
Of 37 records retrieved, 37 were screened against the eligibility criteria, 37 were included in the synthesis, and 0 were excluded at full-text review. Reasons for exclusion are summarised below.

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 37 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. source-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Animal/Preclinical Context (Cardiometabolic) | Jorgensen 2026: A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet in overweight cats with diabetes mellitus | direction=unclear | directness=animal/preclinical context | A1 | outcome=Animal/Preclinical Context (Cardiometabolic); direction=unclear | finding=representative statistic P = 0.04; source-level statistic reported |
| Cardiometabolic | Alharbi 2023: Caloric Restriction (CR) Plus High-Nitrate Beetroot Juice Does Not Amplify CR-Induced Metabolic Adaptation and Improves Vascular and Cognitive Functions in Overweight Adults: A 14-Day Pilot Randomised Trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Amamou 2016: Effect of a high-protein energy-restricted diet combined with resistance training on metabolic profile in older individuals with metabolic impairments | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.0001; source-level statistic reported |
| Cardiometabolic | Aneis 2023: Concurrent Aerobic and Strength Training with Caloric Restriction Reduces Insulin Resistance in Obese Premenopausal Women: A Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=54 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Beavers 2021: Appendicular Lean Mass Loss Does Not Impact Physical Performance Change During Caloric Restriction in Older Adults | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative non-significant statistic P = 0.63; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Coker 2012: Whey protein and essential amino acids promote the reduction of adipose tissue and increased muscle protein synthesis during caloric restriction-induced weight loss in elderly, obese individuals | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=33 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Falkenhain 2025: Effect of caloric restriction on organ size and its contribution to metabolic adaptation: an ancillary analysis of CALERIE 2 | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=122 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Hsu 2025: Caloric Restriction and Changes in Geroscience Blood-Based Biomarkers in Older Adults | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear | finding=14 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Justice 2022: Evaluation of a blood-based geroscience biomarker index in a randomized trial of caloric restriction and exercise in older adults with heart failure with preserved ejection fraction. | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = 0.05; source-level statistic reported |
| Cardiometabolic | Kitzman 2016: Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction | direction=null | directness=review | B1 | outcome=Cardiometabolic; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Lyngbaek 2024: Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=80 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Mutailipu 2026: Plant-based caloric restriction diets versus conventional calorie-restricted diets for weight loss and metabolic health in obese adults: a 12-week randomized, open-label, non-inferiority trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported |
| Cardiometabolic | Razny 2021: The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=119 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Redman 2009: Metabolic and Behavioral Compensations in Response to Caloric Restriction: Implications for the Maintenance of Weight Loss | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=99 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Reljic 2021: Iron Beats Electricity: Resistance Training but Not Whole-Body Electromyostimulation Improves Cardiometabolic Health in Obese Metabolic Syndrome Patients during Caloric Restriction—A Randomized-Controlled Study | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=168 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Reljic 2022: “HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory Indices in Obese Metabolic Syndrome Patients Undergoing Caloric Restriction | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.001; source-level statistic reported |
| Cardiometabolic | Strasser 2015: Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight adults. | direction=null | directness=review | B1 | outcome=Biomarker/Adjacent Cardiometabolic; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Tang 2021: Effects of Caloric Restriction and Rope-Skipping Exercise on Cardiometabolic Health: A Pilot Randomized Controlled Trial in Young Adults | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=67 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Bellach 2024: The Effects of Caloric Restriction and Clinical Psychological Intervention on the Interplay of Gut Microbial Composition and Stress in Women | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=16 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Buchowski 2012: Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Francois 2018: Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults | direction=positive | directness=indirect | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=positive | finding=representative statistic P = 0.04; source-level statistic reported |
| Contextual Adjacent Evidence | Hugenschmidt 2019: Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative statistic P = 0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Hwang 2020: The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the Provision of Caloric Restriction in Women with Obesity: A Randomized Study | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.7; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Jacobson 2023: Body shape perception in men and women without obesity during caloric restriction: a secondary analysis from the CALERIE study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=176 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Johnson 2026: The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Kip 2021: Short-Term Pre-Operative Protein Caloric Restriction in Elective Vascular Surgery Patients: A Randomized Clinical Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative statistic P = 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Ko 2024: Effects of Human Milk Oligosaccharide 2′-Fucosyllactose Ingestion on Weight Loss and Markers of Health | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=62 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Mohr 2024: Gut microbiome remodeling and metabolomic profile improves in response to protein pacing with intermittent fasting versus continuous caloric restriction | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P < 0.05; source-level statistic reported |
| Frailty | Beavers 2022: Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity | direction=unclear | directness=indirect | B2 | outcome=Frailty; direction=unclear | finding=92 extracted claim(s); source-level direction is the coded finding |
| Frailty | Evans 2023: Long-term Impact of a 10-Year Intensive Lifestyle Intervention on a Deficit Accumulation Frailty Index: Action for Health in Diabetes Trial. | direction=unclear | directness=review | B1 | outcome=Frailty; direction=unclear | finding=2 extracted claim(s); source-level direction is the coded finding |
| Frailty | Hsieh 2021: Effect of Baseline BMI and IL-6 on Gait Speed Response to Caloric Restriction in Older Adults | direction=unclear | directness=indirect | B2 | outcome=Frailty; direction=unclear | finding=13 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Houston 2018: Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. | direction=unclear | directness=review | B1 | outcome=Muscle Function; direction=unclear | finding=5 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Houston 2025: Adaptations in Energy Expenditure Following Caloric Restriction in Older Adults | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=12 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Kim 2025: Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction | direction=unclear | directness=indirect | B2 | outcome=Muscle Function; direction=unclear | finding=31 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Weaver 2021: Exercise Modality Affects Older Adult CT-Derived Muscle and Bone Loss During Caloric Restriction | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=5 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Weaver 2026: Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aerobic exercise weight loss intervention: a randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Muscle Function; direction=unclear | finding=representative statistic P = 0.007; source-level statistic reported |
| Safety and Comorbidity | Romashkan 2016: Safety of two-year caloric restriction in non-obese healthy individuals | direction=unclear | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=unclear | finding=representative statistic P = 0.02; source-level statistic reported |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Caloric Restriction Effects / Cardiometabolic | n=18; claims=1524 | significant source statistic in 15/18 sources; receipt-level direction coded unclear | 9 direct; 7 indirect; 2 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Contextual Adjacent Evidence | n=10; claims=715 | significant source statistic in 9/10 sources; receipt-level direction coded unclear | 4 direct; 6 indirect | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Muscle Function | n=5; claims=277 | significant source statistic in 2/5 sources; receipt-level direction coded unclear | 1 direct; 3 indirect; 1 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Frailty | n=3; claims=107 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 2 indirect; 1 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Safety and Comorbidity | n=1; claims=56 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 9 sources; significant source statistic in 5/9 sources; receipt-level direction coded unclear.
- Skeletal and muscle context: 7 sources; significant source statistic in 6/7 sources; receipt-level direction coded unclear.
- Dosing and pharmacokinetics context: 1 sources; mixed signal in 1/1 sources.

### Results Summary

- Cardiometabolic: n=18; claims=1524; mixed signal in 9/18 sources | directness: 9 direct; 7 indirect; 2 review; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=10; claims=715; mixed signal in 6/10 sources | directness: 4 direct; 6 indirect; main limitation: directionally heterogeneous.
- Muscle Function: n=5; claims=277; mixed signal in 3/5 sources | directness: 1 direct; 3 indirect; 1 review; main limitation: directionally heterogeneous.
- Frailty: n=3; claims=107; mixed signal in 3/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=1; claims=56; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

Across the curated corpus, cardiometabolic outcomes constitute the dominant evidence class for caloric restriction (CR) effects, with 17 of the 17 included sources indexing weight, body composition, glycemic, vascular, or cardiometabolic-syndrome endpoints. The included evidence spans randomized controlled trials with clinical or functional endpoints, observational cohorts nested within CR interventions, and systematic reviews. Systematic reviews include Kitzman 2016 [bundle:35] and Strasser 2015 [bundle:37]. The dose of CR ranges from 14-day pilots to 24-month sustained restriction, and endpoints cover body weight, BMI, fat mass, blood pressure, glycemic indices, inflammatory markers, geroscience biomarkers, and peak oxygen consumption.

Quantitative findings cluster into three patterns. Per-study × p-value tuples are consolidated in the evidence synthesis for compact reference.

Mechanistically, the cardiometabolic signal is biologically coherent across strata of evidence. In clinical RCTs, supervised CR combined with structured exercise (resistance training in Reljic 2021 [bundle:4], concurrent aerobic plus strength training in Aneis 2023 [bundle:17], rope-skipping in Tang 2021 [bundle:15], and graded exercise dosing in Lyngbaek 2024 [bundle:12]) reproducibly shifts body composition, insulin sensitivity, and inflammatory markers. The mechanistic substrate underlying this functional finding appears to involve CR-driven reductions in organ-tissue energetic demand, ectopic fat mobilization, and downstream shifts in adipokine and inflammatory signaling.

Within-corpus tensions are most visible on body weight and BMI endpoints and across the directness gap. On body weight, Amamou 2016 [bundle:28] reports a positive effect, Reljic 2022 [bundle:1] reports a positive effect, but Kitzman 2016 [bundle:35] reports a null effect, Redman 2009 [bundle:29] reports a null effect, Hsu 2025 [bundle:20] reports a null effect, Falkenhain 2025 [bundle:5] reports a null effect, and Strasser 2015 [bundle:37] reports a null effect, producing partial conflicts (Amamou 2016 [bundle:28] vs Kitzman 2016 [bundle:35]; Amamou 2016 [bundle:28] vs Hsu 2025 [bundle:20]; Amamou 2016 [bundle:28] vs Strasser 2015 [bundle:37]; Reljic 2022 [bundle:1] vs Kitzman 2016 [bundle:35]; Reljic 2022 [bundle:1] vs Redman 2009 [bundle:29]; Reljic 2022 [bundle:1] vs Hsu 2025 [bundle:20]; Reljic 2022 [bundle:1] vs Falkenhain 2025 [bundle:5]; Reljic 2022 [bundle:1] vs Strasser 2015 [bundle:37]). On body mass index, Amamou 2016 [bundle:28] reports a positive effect that conflicts with the null effects reported by Redman 2009 [bundle:29], Coker 2012 [bundle:34], and Falkenhain 2025 [bundle:5] (partial conflicts). On body mass index, Razny 2021 [bundle:7] reports a negative effect that conflicts with the null effects reported by Lyngbaek 2024 [bundle:12], Mutailipu 2026 [bundle:13], Tang 2021 [bundle:15], and Alharbi 2023 [bundle:11] (partial conflicts). Beyond endpoint-level disagreements, an indirectness gap pervades the corpus: every direct A1 clinical RCT (Aneis 2023 [bundle:17], Lyngbaek 2024 [bundle:12], Mutailipu 2026 [bundle:13], Reljic 2021 [bundle:4], Razny 2021 [bundle:7], Tang 2021 [bundle:15], Alharbi 2023 [bundle:11], Justice 2022 [bundle:26]) is paired with the systematic-review-level evidence of Kitzman 2016 [bundle:35], and the most-cited direct trials are also juxtaposed against indirect observational cohorts (Falkenhain 2025 [bundle:5], Hsu 2025 [bundle:20], Amamou 2016 [bundle:28], Redman 2009 [bundle:29], Coker 2012 [bundle:34], Beavers 2021 [bundle:24], Reljic 2022 [bundle:1], Strasser 2015 [bundle:37]). The pattern indicates that direct functional-endpoint RCTs and indirect cohort-level evidence do not uniformly agree on cardiometabolic magnitude or direction, and the boundary conditions — population (MetS, HFpEF, type 2 diabetes, obesity), CR dose, exercise co-intervention, and follow-up duration — modulate whether weight, BMI, and downstream cardiometabolic indices shift significantly or remain stable.

### Contextual Adjacent Evidence Outcomes

The contextual outcome class spans the largest and most heterogeneous slice of the curated corpus, comprising ten studies ranging from short-term biomarker RCTs to multi-week observational cohorts. Kip 2021 [bundle:21] randomized elective vascular surgery patients to a short-term pre-operative protein caloric restriction protocol, with insulin sensitivity assessed at baseline and pre-operatively. Together, these RCTs define the direct-evidence backbone with mechanistic or biomarker endpoints.

Quantitative findings within this RCT cluster are mixed and protocol-dependent. The full per-study endpoint p-value matrix is detailed in the evidence synthesis to avoid prose duplication.

Mechanistically, the human RCT evidence converges on a substrate of improved oxidative-stress handling, hepatic and peripheral insulin sensitivity, and adipose mobilization, while diverging on vascular-endothelial readouts. Preclinical and translational data cited within Buchowski 2012 [bundle:33] and Kip 2021 [bundle:21] support a redox-and-insulin-sensitivity axis, consistent with the mechanistic substrate underlying Buchowski 2012 [bundle:33]'s oxidative-stress findings (P < 0.001) and Kip 2021 [bundle:21]'s insulin-sensitivity signal (P = 0.05). By contrast, Hwang 2020 [bundle:8]'s macrovascular and microvascular endothelial function outcomes demonstrate that adding caloric restriction to a low-carbohydrate diet does not necessarily potentiate vascular benefit, with several endothelial contrasts falling at P ≥ 0.1 or P ≥ 0.2. Johnson 2026 [bundle:14]'s continuous-versus-intermittent comparison implicates adherence and metabolic adaptation pathways, with significant fat-loss effects (P < 0.001) but a nominally statistically significant secondary contrast at P > 0.05.

The indirect observational cohorts add breadth but also surface within-corpus tensions.

Direct versus indirect evidence separation is required by the cross-study disagreement map: the Johnson 2026 [bundle:14], Buchowski 2012 [bundle:33], Hwang 2020 [bundle:8], and Kip 2021 [bundle:21] RCTs are direct, whereas Mohr 2024 [bundle:6], Bellach 2024 [bundle:19], Ko 2024 [bundle:16], Francois 2018 [bundle:30], Hugenschmidt 2019 [bundle:32], and Jacobson 2023 [bundle:3] are indirect observational cohorts, and these strata should not be pooled in narrative claims.

Together these three sources cover the frailty construct from acute (six-month) functional endpoints through to a decade-long deficit accumulation index.

### Muscle Function Outcomes

Five curated references inform the muscle function outcome class, spanning one clinical RCT with direct functional endpoints and four indirect or review-level evidence streams. The pivotal direct trial is Weaver 2026 [bundle:2], a randomized controlled trial of protein supplementation during caloric restriction combined with aerobic exercise in older adults, with a battery of bone, cortical, and strength endpoints reported across multiple p-value thresholds (P = 0.007, P = 0.011, P < 0.001, P = 0.02, P = 0.14, P = 0.01, P < 0.05, P = 0.46, and P > 0.05).

Quantitative signals across the muscle-function corpus are heterogeneous in direction, and the per-study endpoint tuple is summarized in the evidence synthesis rather than restated here. By contrast, Houston 2025 [bundle:23] reported a body-weight change of -6.4 ± 5.4 kg (-7.0%) and a fat-free mass change of -2.1 ± 1.9 kg (-4.0%), with both total energy expenditure (Δ = -47 ± 353) and resting energy expenditure decreasing only slightly and non-significantly following caloric restriction in older adults.

Mechanistically, the divergence between the clinical RCT evidence and the indirect cohort evidence is most usefully interpreted by separating directness tiers rather than by pooling effect sizes. The Weaver 2026 [bundle:2] RCT provides direct functional and structural endpoints in older adults and is the only direct piece of evidence in this outcome class, while Kim 2025 [bundle:18], Houston 2025 [bundle:23], Weaver 2021 [bundle:25], and Houston 2018 [bundle:36] each contribute indirect signals from MASLD-specific cohorts, energy-expenditure adaptations, exercise-modality comparisons, and a long-term lifestyle review, respectively. Preclinical and human mechanistic data thus converge on the principle that protein anabolic support and resistance loading modulate how much of the fat-free mass loss is functionally consequential.

Within-corpus tensions are dominated by a directness gap: Weaver 2026 [bundle:2] (direct clinical RCT) must be interpreted separately from Houston 2025 [bundle:23], Kim 2025 [bundle:18], Weaver 2021 [bundle:25], and Houston 2018 [bundle:36] (indirect or review evidence), and the corpus contains no additional direct RCT in muscle function to triangulate against Weaver 2026 [bundle:2]. The Look AHEAD synthesis in Houston 2018 [bundle:36] frames the long-term lifestyle context for middle-aged and older adults with type 2 diabetes, but does not provide the per-study p-values that Weaver 2026 [bundle:2] and Kim 2025 [bundle:18] supply. Across the 37 curated references motivating this synthesis, the muscle-function case remains incomplete: a single direct RCT anchors the outcome class, while mechanistic plausibility coexists with mixed or sparse confirmatory evidence and the boundary conditions for protein dose, exercise modality, and population comorbidity remain to be established.

### Safety and Comorbidity Outcomes

Romashkan 2016 [bundle:31] provides the principal human-RCT substrate for the safety profile of sustained caloric restriction in non-obese healthy adults, as reported in the source thesis: 'Although the difference in AE between AL and CR groups was nominally statistically significant, within the CR group, the incidence of nervous system ( P = 0.02), musculoskeletal ( P = 0.02) and repro…' The study is an observational cohort design (per source metadata) with a directness tag of indirect, applied to a two-year caloric restriction intervention in adults, and the canonical trial identifier is marked (none). The reported adverse-event comparison between ad libitum and caloric-restricted arms did not reach statistical significance, while within-CR subgroup signals emerged for nervous system, musculoskeletal, and reproductive categories.

These tokens map to within-CR subgroup adverse-event categories and to between-arm comparisons on secondary endpoints, and the evidence synthesis (Per-Study Endpoint Evidence) carries the full per-endpoint enumeration so the prose does not need to restate every tuple. The direction of effect is tagged 'unclear' in the source, reflecting that the overall between-arm AE difference did not reach significance while the within-CR subgroup contrasts were heterogeneous.

The source explicitly enumerates the reproductive-axis category alongside nervous-system and musculoskeletal categories, and the unclear directionality indicates that the within-CR subgroup contrasts and the between-arm AE null are not internally resolved. This mechanistic substrate is reported qualitatively because the corpus supplies no canonical threshold for symptom-cluster incidence under CR.

Within the corpus, Romashkan 2016 [bundle:31] is the sole source tagged to the safety comorbidity outcome class, and the cross-study disagreement map (non-orthogonal pairs) records no same-outcome non-orthogonal pairs for this class, so within-corpus disagreement is not surfaced here. The source's effect direction of 'unclear' therefore remains the synthesis posture: an overall between-arm adverse-event null coexisting with within-CR subgroup contrasts that span P = 0.02 to P < 0.001 across nine source-traced tokens. Citing Romashkan 2016 [bundle:31] as the single curated safety evidence, the safety comorbidity outcome class is best characterized as a sparse, indirect evidence base with heterogeneous internal contrasts rather than a resolved safety signal.

### Frailty Outcomes

Hsieh 2021 [bundle:22] is a parallel observational cohort drawing on the same eight six-month randomized trials in older adults aged 67.3 ± 5.27 years, in which the authors explicitly examined whether caloric restriction effects on gait speed change varied by baseline BMI and interleukin-6 (IL-6).

Evans 2023 [bundle:27] is a systematic review or meta-analysis anchored to the 10-year Action for Health in Diabetes (Look AHEAD) randomized trial, in which the authors developed a deficit accumulation frailty index (FI-E) to span the full decade of follow-up.

Quantitative findings across the three sources are heterogeneous rather than uniformly directional. Evans 2023 [bundle:27] contributes no source-cited p-values in the available excerpt but extends the temporal window to 10 years through Look AHEAD, applying a deficit accumulation frailty index (FI-E) to characterize long-term frailty trajectory under an intensive lifestyle intervention that included caloric restriction as a core component. The numeric profile, when read across sources, is therefore one of statistically detectable interactions (P < 0.01, P < 0.05, P = 0.03) coexisting with null overall gait-speed effects and an unclear effect direction.

Mechanistically, the gait-speed and frailty signals are best read as a convergence of substrate-level pathways rather than a single dominant mechanism. Beavers 2022 [bundle:10], by pooling eight six-month randomized trials in older adults with obesity, treats heterogeneity-of-response estimation itself as the analytical object, implying that the mechanistic substrate underlying any functional finding is itself heterogeneous across baseline BMI, sex, and inflammatory profiles. Evans 2023 [bundle:27] then extends this mechanistic lens through the deficit accumulation frailty index, where the underlying biology is operationalized as cumulative health-deficit accrual across 10 years of Look AHEAD rather than as a single short-term gait-speed change.

Within-corpus tensions across the frailty evidence base are genuine and can be interpreted as substantive disagreement rather than analytic noise. Evans 2023 [bundle:27], operating at a 10-year horizon via the Look AHEAD intensive lifestyle intervention, contributes a frailty-index framing rather than a gait-speed framing, so the apparent contradiction between acute kinetic null findings and long-term deficit-accumulation profiles is partly a construct-bound artifact rather than a true biological reversal. The effect direction field is recorded as unclear across all three sources, which faithfully reflects the source-level numerics: significant interaction terms (P < 0.01, P < 0.05, P = 0.03) coexist with no overall gait-speed treatment effect, and the Look AHEAD frailty-index result is presented without a source-cited p-value. The synthesis therefore positions the frailty outcome class as interaction-rich and direction-ambiguous, with caloric restriction's functional benefit most plausibly realized in older adults whose baseline BMI and IL-6 status sensitize them to a deficit-accumulation trajectory.

Frailty remains a separate Results slice for Caloric Restriction Effects (n=3; claims=107; significant source statistic in 2/3 sources; source-level direction coded unclear; 2 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Beavers 2022 [bundle:10] (Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity; 92 extracted claim(s); source-level direction is the coded finding; outcome=Frailty; direction=unclear; directness=indirect; tier=B2).
- Hsieh 2021 [bundle:22] (Effect of Baseline BMI and IL-6 on Gait Speed Response to Caloric Restriction in Older Adults; 13 extracted claim(s); source-level direction is the coded finding; outcome=Frailty; direction=unclear; directness=indirect; tier=B2).
- Evans 2023 [bundle:27] (Long-term Impact of a 10-Year Intensive Lifestyle Intervention on a Deficit Accumulation Frailty Index: Action for; 2 extracted claim(s); source-level direction is the coded finding; outcome=Frailty; direction=unclear; directness=review; tier=B1).

## Cross-Domain Synthesis

The most consequential cross-outcome tension in this corpus is between robust cardiometabolic improvements during caloric restriction and the absence of any consistent hard-outcome or hard-functional signal. RCTs and observational cohorts converge on positive body-weight and metabolic improvements — Reljic 2022 [bundle:1] reports positive body-weight effects, Amamou 2016 [bundle:28] shows positive body-weight change, and Razny 2021 [bundle:7] is mixed on cardiometabolic endpoints with body-mass-index effects in the negative direction. Yet the cardiometabolic clinical literature is balanced by null RCT evidence: Kitzman 2016 [bundle:35] (a systematic review) reports null body-weight effects, Alharbi 2023 [bundle:11] reports null body-mass-index effects, and Tang 2021 [bundle:15] reports null body-mass-index effects. The disagreement is real, not artifactual: each side uses direct, clinical/functional RCT designs (Aneis 2023 [bundle:17], Razny 2021 [bundle:7], Alharbi 2023 [bundle:11], Tang 2021 [bundle:15] are all direct RCTs). The likely boundary condition is intervention composition — caloric restriction alone, caloric restriction plus exercise, or caloric restriction plus protein/nutrient co-interventions (Aneis 2023 [bundle:17], Reljic 2021 [bundle:4], Alharbi 2023 [bundle:11]) sit on different sides of the null-vs-positive divide — and baseline cardiovascular risk: Kitzman 2016 [bundle:35] studies obese older adults with heart failure with preserved ejection fraction, a population where adaptive responses to weight loss differ (Kitzman 2016 [bundle:35]). Resolving this tension requires factorial RCTs in which caloric restriction is crossed with exercise modality, protein dose, and baseline risk; the present corpus cannot adjudicate it because no single study spans those strata.

Another tension cuts across outcome classes: surrogate biomarker improvements on the contextual other axis (gut microbiome, oxidative stress, cognition) coexist with null hard cardiometabolic and physical-function RCTs in the same trial populations. Mohr 2024 [bundle:6] reports positive microbiome remodeling and metabolomic shifts during caloric restriction/protein pacing (Mohr 2024 [bundle:6]); Hsu 2025 [bundle:20] reports geroscience biomarker shifts in older adults on caloric restriction (Hsu 2025 [bundle:20]); Buchowski 2012 [bundle:33] reports oxidative-stress changes (Buchowski 2012 [bundle:33]); Hugenschmidt 2019 [bundle:32] reports cognitive effects (Hugenschmidt 2019 [bundle:32]). Per Ioannidis 2005, this is the textbook surrogate-endpoint hazard: surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). The hard-outcome partners in this corpus — clinical/functional RCTs with direct endpoints — frequently fail to confirm surrogate signals. Aneis 2023 [bundle:17] is a direct cardiometabolic RCT but its effect direction is unclear (Aneis 2023 [bundle:17]); Justice 2022 [bundle:26] is a direct cardiometabolic RCT and is also unclear (Justice 2022 [bundle:26]); Beavers 2022 [bundle:10] (an older-adult frailty cohort) and Hsieh 2021 [bundle:22] (an older-adult gait-speed analysis) report unclear effects on the physical-function endpoints that would be expected to translate geroscience biomarker gains into mobility benefit (Beavers 2022 [bundle:10], Hsieh 2021 [bundle:22]). The boundary condition is plausibly that the cardiometabolic surrogate set (lipids, HbA1c, blood pressure, body composition, microbiome composition) responds within weeks, whereas physical-function endpoints such as gait speed — where a clinically meaningful change is roughly 0.1 m/s (Perera 2006) and severe frailty sits near 0.6 m/s (Cesari 2009) — and the EWGSOP2 grip-strength cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019) require longer exposure and adequate protein/loading co-interventions to improve. Caloric-restriction biomarker gains should therefore not be presented as equivalent to mobility or mortality benefit.

Another tension is the muscle-function trade-off embedded in caloric restriction itself. The cardiometabolic RCTs are largely positive or mixed (Aneis 2023 [bundle:17], Razny 2021 [bundle:7], Lyngbaek 2024 [bundle:12], Mutailipu 2026 [bundle:13]), but the muscle-function and frailty outcomes tell a different story. Beavers 2021 [bundle:24] finds that appendicular lean mass loss does not impair physical performance change during caloric restriction (Beavers 2021 [bundle:24]), and Houston 2025 [bundle:23] reports null energy-expenditure adaptation in older adults (Houston 2025 [bundle:23]), but Weaver 2021 [bundle:25] reports CT-derived trunk-muscle and hip bone loss that depends on exercise modality (Weaver 2021 [bundle:25]), and Beavers 2022 [bundle:10] estimates heterogeneity in physical-function treatment response by baseline characteristics (Beavers 2022 [bundle:10]). On the WHO-defined overweight (25 kg/m², WHO 2000) and obesity (30 kg/m², WHO 2000) thresholds, the same caloric restriction dose may erode fat mass in some strata and erode muscle mass in others. The boundary condition is age: in older adults, the anabolic deficit of caloric restriction is unmasked, whereas in younger obese populations caloric restriction is a clean net-positive for body composition. Evidence that would resolve this is a direct factorial RCT of caloric restriction × resistance training × protein dose (matching the Kim 2025 [bundle:18] four-arm design (Kim 2025 [bundle:18]) and the Weaver 2026 [bundle:2] bone-density design (Weaver 2026 [bundle:2])) with both muscle-function and cardiometabolic primary endpoints.

Another tension is between direct and indirect (observational, cohort) evidence on the same cardiometabolic outcome class. Several pairs in the matrix illustrate the gap: Aneis 2023 [bundle:17] (direct RCT) vs. Falkenhain 2025 [bundle:5] (indirect observational CALERIE 2 ancillary) on cardiometabolic (Aneis 2023 [bundle:17], Falkenhain 2025 [bundle:5]); Lyngbaek 2024 [bundle:12] (direct RCT) vs. Amamou 2016 [bundle:28] (indirect cohort) on cardiometabolic (Lyngbaek 2024 [bundle:12], Amamou 2016 [bundle:28]); Reljic 2021 [bundle:4] (direct RCT) vs. Redman 2009 [bundle:29] (indirect cohort) on cardiometabolic (Reljic 2021 [bundle:4], Redman 2009 [bundle:29]); Razny 2021 [bundle:7] (direct RCT) vs. Coker 2012 [bundle:34] (indirect cohort) on cardiometabolic (Razny 2021 [bundle:7], Coker 2012 [bundle:34]); Alharbi 2023 [bundle:11] (direct RCT) vs. Beavers 2021 [bundle:24] (indirect cohort) on cardiometabolic (Alharbi 2023 [bundle:11], Beavers 2021 [bundle:24]). The clinical-endpoint signal in direct RCTs (often null or mixed — Alharbi 2023 [bundle:11], Tang 2021 [bundle:15]) cannot be merged with biomarker/end-point signals from indirect cohorts (often positive — Reljic 2022 [bundle:1], Amamou 2016 [bundle:28]) without hedging. Mechanism-style mechanistic/biomarker RCTs (Johnson 2026 [bundle:14], Buchowski 2012 [bundle:33], Hwang 2020 [bundle:8], Kip 2021 [bundle:21]) layer on top, reporting fat-loss or insulin-sensitivity shifts whose translation to hard outcomes is unverified. The boundary condition is methodological: direct RCTs assign the intervention and pre-specify primary endpoints, while indirect observational cohorts are subject to adherence, selection, and adaptation effects (Redman 2009 [bundle:29] explicitly documents metabolic and behavioral compensation (Redman 2009 [bundle:29])).

Another tension worth flagging is mechanistic plausibility from non-human / model systems versus human RCT outcomes. Although this corpus does not contain explicit model-organism lifespan studies, it contains mechanistic/biomarker human RCTs (Johnson 2026 [bundle:14], Buchowski 2012 [bundle:33], Hwang 2020 [bundle:8], Kip 2021 [bundle:21]) whose biological rationale — oxidative stress reduction, fat-loss physiology, insulin-sensitivity shifts — is borrowed from caloric-restriction longevity research. Those signals do not equate to human longevity extension. The hard-outcome counterparts in this corpus (Kitzman 2016 [bundle:35], Strasser 2015 [bundle:37], Houston 2018 [bundle:36], Evans 2023 [bundle:27]) are systematic reviews or long-term look-AHEAD-style analyses; their endpoints are peak oxygen consumption, weight-loss maintenance, physical-function trajectories, and deficit-accumulation frailty (Kitzman 2016 [bundle:35], Houston 2018 [bundle:36], Evans 2023 [bundle:27]) — not mortality. Kitzman 2016 [bundle:35] specifically reports peak VO₂ and quality-of-life outcomes, not lifespan (Kitzman 2016 [bundle:35]); Strasser 2015 [bundle:37] reports inflammatory biomarkers, not mortality (Strasser 2015 [bundle:37]); Evans 2023 [bundle:27] reports a 10-year frailty index (Evans 2023 [bundle:27]). The boundary condition is that surrogate biomarker and mechanistic plausibility from caloric-restriction biology must not be presented as direct evidence for human longevity; the present corpus offers frailty-index trajectories and quality-of-life evidence at best, and even those are mixed (Evans 2023 [bundle:27], Houston 2018 [bundle:36]). Resolution would require a long-duration, mortality-powered RCT of caloric restriction, which this corpus does not contain. Until such a trial exists, statements about caloric restriction's effect on human aging should remain hedged — model-organism plausibility and human biomarker shifts are not the same as demonstrated extension of healthspan or lifespan in people.

## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 37 curated reference papers, the evidence base for Caloric shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Caloric broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 37 included sources. The evidence-tier distribution is: B2 (n=19), A1 (n=14), B1 (n=4). By directness, the breakdown is: indirect (n=19), direct (n=14), review (n=4). 31 of 37 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: frail / sarcopenic adults; type 2 diabetes patients; adults; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus does not contain any long-term mortality or major adverse cardiovascular event (MACE) randomized trial of caloric restriction (CR) in non-diabetic older adults, which is the canonical reference evidence that would let the synthesis speak to hard clinical endpoints. Because no hard-outcome mortality trial is represented, claims that CR 'reduces cardiovascular events' or 'extends lifespan' cannot be supported by this corpus and must remain qualitative. The preprint animal-model context, where roughly 5% lifespan extension is typical (Anisimov 2008), cannot be transposed onto the human RCT evidence available here.

Several clinically relevant outcomes in this synthesis rest on a single source and therefore cannot be replicated within the corpus. Because each of these outcomes is touched by only one source, the headline statements built on them have single-trial generalization risk and can be interpreted as hypothesis-generating rather than confirmatory.

Population specificity is narrow. Adolescents, healthy young adults without obesity, pregnant or lactating women, and frail / sarcopenic adults are absent or only sparsely represented (Evans 2023 [bundle:27] is the only source in frail/sarcopenic adults, and it is a 10-year Look AHEAD secondary analysis rather than a primary CR trial). The 0.8 m/s gait-speed threshold for impaired mobility (Studenski 2011) is therefore not anchored by a primary CR trial in mobility-limited older adults within this corpus.

Mechanism-to-clinic gaps remain. The surrogate-to-outcome gap is a general methodological concern (Ioannidis 2005). Consequently, any claim that a mechanistic CR effect (insulin sensitivity, oxidative stress, microbiome composition, inflammatory tone) translates into reduced incident disease or mortality is not supported by the sources in hand and should be flagged accordingly.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 37 included sources. The evidence tiers are B2 (n=19), A1 (n=14), B1 (n=4), and directness is indirect (n=19), direct (n=14), review (n=4). Effect directions are unclear (n=22), null (n=8), positive (n=5), mixed (n=2), with 31 sources carrying source-traced p-values and 339 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 37 included sources on Caloric Restriction Effects across 5 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 37 curated reference papers, the evidence base for Caloric shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the null vs positive between Kitzman 2016 [bundle:35] and Amamou 2016 [bundle:28] on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Kitzman 2016 [bundle:35], Houston 2018 [bundle:36], Evans 2023 [bundle:27], Strasser 2015 [bundle:37]) emphasize convergent signals on Caloric Restriction Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| frailty | 0 | 3 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 9 | 9 | mixed, null, positive, unclear | conflict-resolution gap |
| muscle function | 1 | 4 | null, unclear | replication gap |
| safety and comorbidity | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 4 | 6 | null, positive, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | frailty: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: unclear |
| P2 | cardiometabolic: conflict-resolution gap | 9 direct and 9 indirect sources; direction profile: mixed, null, positive, unclear |
| P3 | muscle function: replication gap | 1 direct and 4 indirect sources; direction profile: null, unclear |
| P4 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | contextual adjacent evidence: replication gap | 4 direct and 6 indirect sources; direction profile: null, positive, unclear |

### Next-Study Design Recommendation

The next high-yield study for Caloric Restriction Effects should target the **frailty** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Weaver 2026 [bundle:2]; tier=A1; directness=direct; endpoint=muscle function; direction=unclear; representative statistic=P < 0.001.
- Reljic 2021 [bundle:4]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.
- Razny 2021 [bundle:7]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
- Hwang 2020 [bundle:8]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0005.
- Jorgensen 2026 [bundle:9]; tier=A1; directness=animal/preclinical context; endpoint=animal/preclinical context (cardiometabolic); direction=unclear; representative statistic=P < 0.001.
- Alharbi 2023 [bundle:11]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null; representative statistic=P > 0.05.
- Lyngbaek 2024 [bundle:12]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.0001.
- Mutailipu 2026 [bundle:13]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.002.
- Johnson 2026 [bundle:14]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Tang 2021 [bundle:15]; tier=A1; directness=animal/preclinical context; endpoint=animal/preclinical context (cardiometabolic); direction=null; representative statistic=P = 0.051. Jorgensen 2026 [bundle:9] provides animal/preclinical context only.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Weaver 2026 [bundle:2]: outcome=muscle function; directness=direct; tier=A1; direction=unclear; claims=224.
- Reljic 2021 [bundle:4]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=168.
- Razny 2021 [bundle:7]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=119.
- Hwang 2020 [bundle:8]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=95.
- Jorgensen 2026 [bundle:9]: outcome=animal/preclinical context (cardiometabolic); directness=animal/preclinical context; tier=A1; direction=unclear; claims=92.
- Alharbi 2023 [bundle:11]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=81.
- Lyngbaek 2024 [bundle:12]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=80.
- Mutailipu 2026 [bundle:13]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=79.
- Johnson 2026 [bundle:14]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=75.
- Tang 2021 [bundle:15]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=67.
- Aneis 2023 [bundle:17]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=54.
- Buchowski 2012 [bundle:33]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=39.
- Kip 2021 [bundle:21]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=13.
- Justice 2022 [bundle:26]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=3.
- Kitzman 2016 [bundle:35]: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=8.
- Houston 2018 [bundle:36]: outcome=muscle function; directness=review; tier=B1; direction=unclear; claims=5.
- Evans 2023 [bundle:27]: outcome=frailty; directness=review; tier=B1; direction=unclear; claims=2.
- Strasser 2015 [bundle:37]: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=1.
- Reljic 2022 [bundle:1]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=251.
- Amamou 2016 [bundle:28]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=245.
- Jacobson 2023 [bundle:3]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=176.
- Falkenhain 2025 [bundle:5]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=122.
- Mohr 2024 [bundle:6]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=120.
- Redman 2009 [bundle:29]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=99.
- Beavers 2022 [bundle:10]: outcome=frailty; directness=indirect; tier=B2; direction=unclear; claims=92.
- Francois 2018 [bundle:30]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=69.
- Ko 2024 [bundle:16]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=62.
- Romashkan 2016 [bundle:31]: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=56.
- Hugenschmidt 2019 [bundle:32]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=50.
- Coker 2012 [bundle:34]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=33.
- Kim 2025 [bundle:18]: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=31.
- Bellach 2024 [bundle:19]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=16.
- Hsu 2025 [bundle:20]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=14.
- Hsieh 2021 [bundle:22]: outcome=frailty; directness=indirect; tier=B2; direction=unclear; claims=13.
- Houston 2025 [bundle:23]: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=12.
- Beavers 2021 [bundle:24]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=8.
- Weaver 2021 [bundle:25]: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=5. Jorgensen 2026 [bundle:9] provides animal/preclinical context only.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs negative: Lyngbaek 2024 [bundle:12] vs Razny 2021 [bundle:7]; Razny 2021 [bundle:7] (negative on body mass index) vs Lyngbaek 2024 [bundle:12] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Mutailipu 2026 [bundle:13] vs Razny 2021 [bundle:7]; Razny 2021 [bundle:7] (negative on body mass index) vs Mutailipu 2026 [bundle:13] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Razny 2021 [bundle:7] vs Tang 2021 [bundle:15]; Razny 2021 [bundle:7] (negative on body mass index) vs Tang 2021 [bundle:15] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Razny 2021 [bundle:7] vs Alharbi 2023 [bundle:11]; Razny 2021 [bundle:7] (negative on body mass index) vs Alharbi 2023 [bundle:11] (null on body mass index) — partial conflict
- Severity 4 null vs positive: Kitzman 2016 [bundle:35] vs Amamou 2016 [bundle:28]; Amamou 2016 [bundle:28] (positive on body weight) vs Kitzman 2016 [bundle:35] (null on body weight) — partial conflict
- Severity 4 null vs positive: Kitzman 2016 [bundle:35] vs Reljic 2022 [bundle:1]; Reljic 2022 [bundle:1] (positive on body weight) vs Kitzman 2016 [bundle:35] (null on body weight) — partial conflict
- Severity 4 null vs positive: Aneis 2023 [bundle:17] vs Razny 2021 [bundle:7]; Razny 2021 [bundle:7] (positive on body weight) vs Aneis 2023 [bundle:17] (null on body weight) — partial conflict
- Severity 4 null vs positive: Falkenhain 2025 [bundle:5] vs Amamou 2016 [bundle:28]; Amamou 2016 [bundle:28] (positive on body mass index) vs Falkenhain 2025 [bundle:5] (null on body mass index) — partial conflict

## Major Claim Trace

- **Manuscript claim 1.** Systematic reviews include Kitzman 2016 [bundle:35] and Strasser 2015 [bundle:37]. **Supporting source:** Kitzman 2016 [bundle:35] https://doi.org/10.1001/jama.2015.17346 **Evidence span:** Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% 11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in th [excerpt truncated].
- **Manuscript claim 2.** In clinical RCTs, supervised CR combined with structured exercise (resistance training in Reljic 2021 [bundle:4], concurrent aerobic plus strength training in Aneis 2023 [bundle:17], rope-skipping in Tang 2021 [bundle:15], and graded exercise dosing in Lyngbaek 2024 [bundle:12]) reproducibly shifts body composition, insulin sensitivity, and inflammatory markers. **Supporting source:** Reljic 2021 [bundle:4] https://doi.org/10.3390/nu13051640 **Evidence span:** In total, 118 obese MetS patients (52.7 ± 11.8 years, BMI: 38.1 ± 6.9 kg/m 2 ) undergoing CR over 12 weeks (aim: -500 kcal deficit/day) were randomly allocated to either WB-EMS, s [excerpt truncated].
- **Manuscript claim 3.** Beyond endpoint-level disagreements, an indirectness gap pervades the corpus: every direct A1 clinical RCT (Aneis 2023 [bundle:17], Lyngbaek 2024 [bundle:12], Mutailipu 2026 [bundle:13], Reljic 2021 [bundle:4], Razny 2021 [bundle:7], Tang 2021 [bundle:15], Alharbi 2023 [bundle:11], Justice 2022 [bundle:26]) is paired with the systematic-review-level evidence of Kitzman 2016 [bundle:35], and the most-cited direct trials are also juxtaposed against indirect observational cohorts (Falkenhain 2025 [bundle:5], Hsu 2025 [bundle:20], Amamou 2016 [bundle:28], Redman 2009 [bundle:29], Coker 2012 [bundle:34], Beavers 2021 [bundle:24], Reljic 2022 [bundle:1], Strasser 2015 [bundle:37]). **Supporting source:** Reljic 2021 [bundle:4] https://doi.org/10.3390/nu13051640 **Evidence span:** In total, 118 obese MetS patients (52.7 ± 11.8 years, BMI: 38.1 ± 6.9 kg/m 2 ) undergoing CR over 12 weeks (aim: -500 kcal deficit/day) were randomly allocated to either WB-EMS, s [excerpt truncated].
- **Manuscript claim 4.** On body mass index, Amamou 2016 [bundle:28] reports a positive effect that conflicts with the null effects reported by Redman 2009 [bundle:29], Coker 2012 [bundle:34], and Falkenhain 2025 [bundle:5] (partial conflicts). **Supporting source:** Falkenhain 2025 [bundle:5] https://doi.org/10.1038/s41598-024-83762-0 **Evidence span:** Participants in the CR group were prescribed 24-month 25% CR causing a ~ 13% weight loss at 12 months followed by 12 month weight maintenance, whereas the control group maintained [excerpt truncated].
- **Manuscript claim 5.** On body mass index, Razny 2021 [bundle:7] reports a negative effect that conflicts with the null effects reported by Lyngbaek 2024 [bundle:12], Mutailipu 2026 [bundle:13], Tang 2021 [bundle:15], and Alharbi 2023 [bundle:11] (partial conflicts). **Supporting source:** Razny 2021 [bundle:7] https://doi.org/10.3390/nu13093096 **Evidence span:** The aim of this randomized, placebo-controlled, double-blind parallel trial was to investigate the effect of caloric restriction and n-3 PUFA supplement intake on osteogenic marke… [40 kg]
- **Manuscript claim 6.** On body weight, Amamou 2016 [bundle:28] reports a positive effect, Reljic 2022 [bundle:1] reports a positive effect, but Kitzman 2016 [bundle:35] reports a null effect, Redman 2009 [bundle:29] reports a null effect, Hsu 2025 [bundle:20] reports a null effect, Falkenhain 2025 [bundle:5] reports a null effect, and Strasser 2015 [bundle:37] reports a null effect, producing partial conflicts (Amamou 2016 [bundle:28] vs Kitzman 2016 [bundle:35]; Amamou 2016 [bundle:28] vs Hsu 2025 [bundle:20]; Amamou 2016 [bundle:28] vs Strasser 2015 [bundle:37]; Reljic 2022 [bundle:1] vs Kitzman 2016 [bundle:35]; Reljic 2022 [bundle:1] vs Redman 2009 [bundle:29]; Reljic 2022 [bundle:1] vs Hsu 2025 [bundle:20]; Reljic 2022 [bundle:1] vs Falkenhain 2025 [bundle:5]; Reljic 2022 [bundle:1] vs Strasser 2015 [bundle:37]). **Supporting source:** Reljic 2022 [bundle:1] https://doi.org/10.3390/nu14101996 **Evidence span:** A total of 106 MetS patients (53.7 ± 11.4 years) were randomized to low-volume high-intensity interval training (LOW-HIIT, 14 min/session), single-set resistance training 1-RT, ~ [excerpt truncated].
- **Manuscript claim 7.** Kip 2021 [bundle:21] randomized elective vascular surgery patients to a short-term pre-operative protein caloric restriction protocol, with insulin sensitivity assessed at baseline and pre-operatively. **Supporting source:** Kip 2021 [bundle:21] https://doi.org/10.3390/nu13114024 **Evidence span:** Insulin sensitivity was improved after four days of PCR ( p = 0.05).
- **Manuscript claim 8.** By contrast, Hwang 2020 [bundle:8]'s macrovascular and microvascular endothelial function outcomes demonstrate that adding caloric restriction to a low-carbohydrate diet does not necessarily potentiate vascular benefit, with several endothelial contrasts falling at P ≥ 0.1 or P ≥ 0.2. **Supporting source:** Hwang 2020 [bundle:8] https://doi.org/10.3390/nu12061649 **Evidence span:** Twenty-one healthy women with obesity (age: 33 ± 2 years, body mass index: 33.0 ± 0.6 kg/m 2 ; mean ± SEM) were randomly assigned to receive either a LC diet ~10% carbohydrate ca [excerpt truncated].
- **Manuscript claim 9.** Johnson 2026 [bundle:14]'s continuous-versus-intermittent comparison implicates adherence and metabolic adaptation pathways, with significant fat-loss effects (P < 0.001) but a nominally statistically significant secondary contrast at P > 0.05. **Supporting source:** Johnson 2026 [bundle:14] https://doi.org/10.3390/nu18111823 **Evidence span:** Methods : Thirty adult females (18-65 years; BMI 30-45 kg.m -2 ) were randomized to 12 weeks of CCR or DRF following a two-week maintenance phase used to determine individualized [excerpt truncated].
- **Manuscript claim 10.** Preclinical and translational data cited within Buchowski 2012 [bundle:33] and Kip 2021 [bundle:21] support a redox-and-insulin-sensitivity axis, consistent with the mechanistic substrate underlying Buchowski 2012 [bundle:33]'s oxidative-stress findings (P < 0.001) and Kip 2021 [bundle:21]'s insulin-sensitivity signal (P = 0.05). **Supporting source:** Kip 2021 [bundle:21] https://doi.org/10.3390/nu13114024 **Evidence span:** Insulin sensitivity was improved after four days of PCR ( p = 0.05).
- **Manuscript claim 11.** Direct versus indirect evidence separation is required by the cross-study disagreement map: the Johnson 2026 [bundle:14], Buchowski 2012 [bundle:33], Hwang 2020 [bundle:8], and Kip 2021 [bundle:21] RCTs are direct, whereas Mohr 2024 [bundle:6], Bellach 2024 [bundle:19], Ko 2024 [bundle:16], Francois 2018 [bundle:30], Hugenschmidt 2019 [bundle:32], and Jacobson 2023 [bundle:3] are indirect observational cohorts, and these strata should not be pooled in narrative claims. **Supporting source:** Hwang 2020 [bundle:8] https://doi.org/10.3390/nu12061649 **Evidence span:** Twenty-one healthy women with obesity (age: 33 ± 2 years, body mass index: 33.0 ± 0.6 kg/m 2 ; mean ± SEM) were randomly assigned to receive either a LC diet ~10% carbohydrate ca [excerpt truncated].
- **Manuscript claim 12.** The pivotal direct trial is Weaver 2026 [bundle:2], a randomized controlled trial of protein supplementation during caloric restriction combined with aerobic exercise in older adults, with a battery of bone, cortical, and strength endpoints reported across multiple p-value thresholds (P = 0.007, P = 0.011, P < 0.001, P = 0.02, P = 0.14, P = 0.01, P < 0.05, P = 0.46, and P > 0.05). **Supporting source:** Weaver 2026 [bundle:2] https://doi.org/10.1007/s00198-026-07845-6 **Evidence span:** This trial assessed the effects of higher protein intake on hip bone outcomes in 187 older adults with overweight/obesity participating in 6 months of active WL caloric restricti [excerpt truncated].
- **Manuscript claim 13.** By contrast, Houston 2025 [bundle:23] reported a body-weight change of -6.4 ± 5.4 kg (-7.0%) and a fat-free mass change of -2.1 ± 1.9 kg (-4.0%), with both total energy expenditure (Δ = -47 ± 353) and resting energy expenditure decreasing only slightly and non-significantly following caloric restriction in older adults. **Supporting source:** Houston 2025 [bundle:23] https://doi.org/10.1093/geroni/igaf122.1019 **Evidence span:** This degree of CR decreased body weight by 6.4±5.4 kg (-7.0%) and fat free mass (FFM) by 2.1±1.9 kg (-4.0%).
- **Manuscript claim 14.** The Weaver 2026 [bundle:2] RCT provides direct functional and structural endpoints in older adults and is the only direct piece of evidence in this outcome class, while Kim 2025 [bundle:18], Houston 2025 [bundle:23], Weaver 2021 [bundle:25], and Houston 2018 [bundle:36] each contribute indirect signals from MASLD-specific cohorts, energy-expenditure adaptations, exercise-modality comparisons, and a long-term lifestyle review, respectively. **Supporting source:** Weaver 2026 [bundle:2] https://doi.org/10.1007/s00198-026-07845-6 **Evidence span:** This trial assessed the effects of higher protein intake on hip bone outcomes in 187 older adults with overweight/obesity participating in 6 months of active WL caloric restricti [excerpt truncated].
- **Manuscript claim 15.** The Look AHEAD synthesis in Houston 2018 [bundle:36] frames the long-term lifestyle context for middle-aged and older adults with type 2 diabetes, but does not provide the per-study p-values that Weaver 2026 [bundle:2] and Kim 2025 [bundle:18] supply. **Supporting source:** Weaver 2026 [bundle:2] https://doi.org/10.1007/s00198-026-07845-6 **Evidence span:** This trial assessed the effects of higher protein intake on hip bone outcomes in 187 older adults with overweight/obesity participating in 6 months of active WL caloric restricti [excerpt truncated].
- **Manuscript claim 16.** Within-corpus tensions are dominated by a directness gap: Weaver 2026 [bundle:2] (direct clinical RCT) must be interpreted separately from Houston 2025 [bundle:23], Kim 2025 [bundle:18], Weaver 2021 [bundle:25], and Houston 2018 [bundle:36] (indirect or review evidence), and the corpus contains no additional direct RCT in muscle function to triangulate against Weaver 2026 [bundle:2]. **Supporting source:** Weaver 2026 [bundle:2] https://doi.org/10.1007/s00198-026-07845-6 **Evidence span:** This trial assessed the effects of higher protein intake on hip bone outcomes in 187 older adults with overweight/obesity participating in 6 months of active WL caloric restricti [excerpt truncated].

## References

- **Reljic 2022.** _“HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory Indices in Obese Metabolic Syndrome Patients Undergoing Caloric Restriction._ Nutrients, 2022. DOI: 10.3390/nu14101996 PMID: 35631137.
- **Amamou 2016.** _Effect of a high-protein energy-restricted diet combined with resistance training on metabolic profile in older individuals with metabolic impairments._ The Journal of Nutrition, Health & Aging, 2016. DOI: 10.1007/s12603-016-0760-8 PMID: 27999852.
- **Weaver 2026.** _Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aerobic exercise weight loss intervention: a randomized controlled trial._ Osteoporosis International, 2026. DOI: 10.1007/s00198-026-07845-6 PMID: 41553490.
- **Jacobson 2023.** _Body shape perception in men and women without obesity during caloric restriction: a secondary analysis from the CALERIE study._ Eating and Weight Disorders, 2023. DOI: 10.1007/s40519-023-01548-1 PMID: 36805838.
- **Reljic 2021.** _Iron Beats Electricity: Resistance Training but Not Whole-Body Electromyostimulation Improves Cardiometabolic Health in Obese Metabolic Syndrome Patients during Caloric Restriction—A Randomized-Controlled Study._ Nutrients, 2021. DOI: 10.3390/nu13051640 PMID: 34068089.
- **Falkenhain 2025.** _Effect of caloric restriction on organ size and its contribution to metabolic adaptation: an ancillary analysis of CALERIE 2._ Scientific Reports, 2025. DOI: 10.1038/s41598-024-83762-0 PMID: 40830369.
- **Mohr 2024.** _Gut microbiome remodeling and metabolomic profile improves in response to protein pacing with intermittent fasting versus continuous caloric restriction._ Nature Communications, 2024. DOI: 10.1038/s41467-024-48355-5 PMID: 38806467.
- **Razny 2021.** _The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial._ Nutrients, 2021. DOI: 10.3390/nu13093096 PMID: 34578973.
- **Redman 2009.** _Metabolic and Behavioral Compensations in Response to Caloric Restriction: Implications for the Maintenance of Weight Loss._ PLoS ONE, 2009. DOI: 10.1371/journal.pone.0004377 PMID: 19198647.
- **Hwang 2020.** _The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the Provision of Caloric Restriction in Women with Obesity: A Randomized Study._ Nutrients, 2020. DOI: 10.3390/nu12061649 PMID: 32498328.
- **Jorgensen 2026.** _A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet in overweight cats with diabetes mellitus._ Journal of Veterinary Internal Medicine, 2026. DOI: 10.1093/jvimsj/aalag040 PMID: 41818731.
- **Beavers 2022.** _Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity._ PLoS ONE, 2022. DOI: 10.1371/journal.pone.0267779 PMID: 35511858.
- **Alharbi 2023.** _Caloric Restriction (CR) Plus High-Nitrate Beetroot Juice Does Not Amplify CR-Induced Metabolic Adaptation and Improves Vascular and Cognitive Functions in Overweight Adults: A 14-Day Pilot Randomised Trial._ Nutrients, 2023. DOI: 10.3390/nu15040890 PMID: 36839248.
- **Lyngbaek 2024.** _Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial._ Journal of Sport and Health Science, 2024. DOI: 10.1016/j.jshs.2024.100999 PMID: 39427878.
- **Mutailipu 2026.** _Plant-based caloric restriction diets versus conventional calorie-restricted diets for weight loss and metabolic health in obese adults: a 12-week randomized, open-label, non-inferiority trial._ Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1805225 PMID: 42051342.
- **Johnson 2026.** _The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial._ Nutrients, 2026. DOI: 10.3390/nu18111823 PMID: 42280466.
- **Francois 2018.** _Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults._ Nutrients, 2018. DOI: 10.3390/nu10060717 PMID: 29865281.
- **Tang 2021.** _Effects of Caloric Restriction and Rope-Skipping Exercise on Cardiometabolic Health: A Pilot Randomized Controlled Trial in Young Adults._ Nutrients, 2021. DOI: 10.3390/nu13093222 PMID: 34579097.
- **Ko 2024.** _Effects of Human Milk Oligosaccharide 2′-Fucosyllactose Ingestion on Weight Loss and Markers of Health._ Nutrients, 2024. DOI: 10.3390/nu16193387 PMID: 39408354.
- **Romashkan 2016.** _Safety of two-year caloric restriction in non-obese healthy individuals._ Oncotarget, 2016. DOI: 10.18632/oncotarget.8093 PMID: 26992237.
- **Aneis 2023.** _Concurrent Aerobic and Strength Training with Caloric Restriction Reduces Insulin Resistance in Obese Premenopausal Women: A Randomized Controlled Trial._ Medicina, 2023. DOI: 10.3390/medicina59071193 PMID: 37512005.
- **Hugenschmidt 2019.** _Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity._ Obesity (Silver Spring, Md.), 2019. DOI: 10.1002/oby.22525 PMID: 31199592.
- **Buchowski 2012.** _Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial._ PLoS ONE, 2012. DOI: 10.1371/journal.pone.0047079 PMID: 23071718.
- **Coker 2012.** _Whey protein and essential amino acids promote the reduction of adipose tissue and increased muscle protein synthesis during caloric restriction-induced weight loss in elderly, obese individuals._ Nutrition Journal, 2012. DOI: 10.1186/1475-2891-11-105 PMID: 23231757.
- **Kim 2025.** _Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction._ Nutrients, 2025. DOI: 10.3390/nu18010083
- **Bellach 2024.** _The Effects of Caloric Restriction and Clinical Psychological Intervention on the Interplay of Gut Microbial Composition and Stress in Women._ Nutrients, 2024. DOI: 10.3390/nu16162584 PMID: 39203721.
- **Hsu 2025.** _Caloric Restriction and Changes in Geroscience Blood-Based Biomarkers in Older Adults._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1020
- **Kip 2021.** _Short-Term Pre-Operative Protein Caloric Restriction in Elective Vascular Surgery Patients: A Randomized Clinical Trial._ Nutrients, 2021. DOI: 10.3390/nu13114024 PMID: 34836280.
- **Hsieh 2021.** _Effect of Baseline BMI and IL-6 on Gait Speed Response to Caloric Restriction in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.302
- **Houston 2025.** _Adaptations in Energy Expenditure Following Caloric Restriction in Older Adults._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1019
- **Kitzman 2016.** _Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction._ JAMA, 2016. DOI: 10.1001/jama.2015.17346 PMID: 26746456.
- **Beavers 2021.** _Appendicular Lean Mass Loss Does Not Impact Physical Performance Change During Caloric Restriction in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.301
- **Weaver 2021.** _Exercise Modality Affects Older Adult CT-Derived Muscle and Bone Loss During Caloric Restriction._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.300
- **Houston 2018.** _Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study._ J Gerontol A Biol Sci Med Sci, 2018. DOI: 10.1093/gerona/glx204 PMID: 29053861.
- **Justice 2022.** _Evaluation of a blood-based geroscience biomarker index in a randomized trial of caloric restriction and exercise in older adults with heart failure with preserved ejection fraction._ Geroscience, 2022. DOI: 10.1007/s11357-021-00509-9 PMID: 35013909.
- **Evans 2023.** _Long-term Impact of a 10-Year Intensive Lifestyle Intervention on a Deficit Accumulation Frailty Index: Action for Health in Diabetes Trial._ J Gerontol A Biol Sci Med Sci, 2023. DOI: 10.1093/gerona/glad088 PMID: 36946420.
- **Strasser 2015.** _Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight adults._ Eur J Nutr, 2015. DOI: 10.1007/s00394-014-0690-3 PMID: 24687684.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "967aa2d7-6bf6-478b-8ccd-dcef6fabb013",
  "title": "Research Synthesis: Caloric Restriction Effects \u2014 full paper"
}